News >

Avelumab/Axitinib Combo Improves PFS in Frontline RCC

Jason M. Broderick @jasoncology
Published: Tuesday, Sep 11, 2018

Chris Boshoff, MD, PhD

Chris Boshoff, MD, PhD
Combining the PD-L1 inhibitor avelumab (Bavencio) with the VEGF inhibitor axitinib (Inlyta) significantly improved progression-free survival (PFS) compared with sunitinib (Sutent) in treatment-naïve patients with advanced renal cell carcinoma (RCC), according to findings from the phase III JAVELIN Renal 101 study.

The global, phase III JAVELIN Renal 101 trial randomized 886 patients with advanced RCC to first-line treatment with the combination of avelumab (10 mg/kg IV every 2 weeks) plus axitinib (5 mg orally twice daily) or monotherapy with sunitinib (50 mg orally once daily, 4 weeks on/2 weeks off). The primary endpoint was improved PFS or overall survival (OS) in patients with PD-L1 expression >1%. Per study design, the secondary outcome measure of improved PFS or OS in all-comers was analyzed only after the primary objective was achieved.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x